ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

8:30AM-10:30AM: Abstract Number: 1533

Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1574

Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

8:30AM-10:30AM: Abstract Number: 1657

Comprehensive Assessment of Multimorbidity Burden in a Population-based Cohort of Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

8:30AM-10:30AM: Abstract Number: 1595

Concern About the COVID-19 Pandemic and Community Mobility Among Systemic Lupus Erythematosus Patients

Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Abstract Number: 1519

Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers

Immunological Complications of Therapy Poster (1516–1529)

8:30AM-10:30AM: Abstract Number: 1863

Consistent Efficacy with Apremilast in Men and Women to Treat Oral Ulcers Associated with Behçet’s Syndrome: Results from Phase 3 Researching Oral Apremilast Safety and Efficacy in Behçet’s Disease (RELIEF) Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

8:30AM-10:30AM: Abstract Number: 1731

Construction and Validation of a Reproductive Health Questionnaire for Women with Rheumatic Diseases

Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

8:30AM-10:30AM: Abstract Number: 1850

Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Two-Year Data from SENSCIS-ON

Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

8:30AM-10:30AM: Abstract Number: 1513

Control of T Cell Tolerance by the NR4A Family of Nuclear Receptors

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (1507–1515)

8:30AM-10:30AM: Abstract Number: 1812

Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1671

COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

8:30AM-10:30AM: Abstract Number: 1637

Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1594

COVID-19 Pandemic-Related Changes in Health Routines and Self-Reported Physical Functioning Among Systemic Lupus Erythematosus Patients

Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Abstract Number: 1603

COVID-19 Vaccination Experience in Patients with Rheumatoid Arthritis Treated at the Cleveland VA Medical Center

Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Abstract Number: 1524

COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population

Immunological Complications of Therapy Poster (1516–1529)

«Previous Page
1
…
5
6
7
8
9
…
33
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.